title: Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis.
abstract: BACKGROUND
  Balsalazide is well tolerated and effective in treating acute ulcerative colitis. VSL#3 is a probiotic cocktail proven to be effective in preventing flare-ups of chronic pouchitis. We compared the efficacy and safety of low-dose balsalazide (2.25 g/day) plus 3 g/day VLS#3 (group A) with medium-dose balsalazide alone (group B) and with mesalazine (group C) in the treatment of mild-to-moderate active ulcerative colitis.
  
  
  METHODS
  Ninety patients (30 per group) were randomly enrolled, with a treatment duration of 8 weeks. Efficacy was assessed by symptoms assessment, endoscopic appearance, and histological evaluation.
  
  
  RESULTS
  Balsalazide/VSL#3 was significantly superior to balsalazide alone and to mesalazine in obtaining remission: 24 patients of group A were in remission [per-protocol: 85.71% (C.I.95%: 62-96), on intention-to-treat: 80% (C.I.95%: 59-91)], while 21 group B [per-protocol: 80.77% (C.I. 95%: 51-82), on intention-to-treat: 77% (C.I.95%: 43-81)] and 16 group C patients [per-protocol: 72.73% (C.I. 95%: 30-75), on intention-to-treat: 53.33% (C.I.95%: 42-62)] were in remission (p<0.02). Balsalazide with or without VSL#3 was better tolerated than mesalazine: two group C patients were withdrawn from the study because of severe side-effects; 1 group A (3.33%), 3 group B (10%) and 4 group C (13.33%) patients experienced slight side-effects. The balsalazide/VSL#3 combination was faster in obtaining remission than balsalazide alone or mesalazine (4, 7.5, and 13 days in groups A, B and C, respectively) and also better in improving all parameters evaluated.
  
  
  CONCLUSIONS
  Balsalazide/VSL#3 may be a very good choice in the treatment of active mild-to-moderate active ulcerative colitis instead of balsalazide alone or mesalazine.
authors.affiliation: Digestive Endoscopy Unit, Lorenzo Bonomo Hospital, Andria (BA), Italy. antotursi@tiscali.it
authors.forename: Antonio
authors.initials: A
authors.lastname: Tursi
authors.forename: Giovanni
authors.initials: G
authors.lastname: Brandimarte
authors.forename: Gian Marco
authors.initials: GM
authors.lastname: Giorgetti
authors.forename: Giacomo
authors.initials: G
authors.lastname: Forti
authors.forename: Maria Ester
authors.initials: ME
authors.lastname: Modeo
authors.forename: Andrea
authors.initials: A
authors.lastname: Gigliobianco
mesh_terms: D000328:Adult; D000368:Aged; D000636:Aminosalicylic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D019804:Mesalamine / Q000627:therapeutic use; D008875:Middle Aged; D010659:Phenylhydrazines; D019936:Probiotics / Q000627:therapeutic use*
chemical_list: D000636:Aminosalicylic Acids; D010659:Phenylhydrazines; D019804:Mesalamine; C038637:balsalazide